Multiple myeloma cells depend heavily on the survival protein MCL1 to evade apoptosis, traditionally degraded via the proteasome pathway. Proteasome inhibitors, a standard treatment for multiple myeloma, cause an accumulation of unwanted proteins, inducing toxic stress to the cancer cells. However, the cells often evade death by activating autophagy—a cellular recycling mechanism—enabling resistance and resumption of tumor growth.

Challenging the prevailing strategy of blocking autophagy to combat drug resistance, researchers at VCU devised an AUTAC molecule that reroutes autophagy to selectively degrade MCL1. By forcing MCL1 degradation through the lysosome instead of the proteasome, this approach circumvents typical resistance mechanisms. The combined use of AUTAC with proteasome inhibitors in preclinical models resulted in a notable 50% reduction in multiple myeloma cell viability within 48 hours, providing compelling proof of principle for this dual-targeted strategy.

Targeted protein degradation, the foundation of this method, represents a paradigm shift from conventional inhibitors that merely block protein function; instead, it eliminates the proteins completely. Such precision diminishes the likelihood of cancer cells adapting through compensatory pathways, offering a promising avenue to overcome tumor resilience.

A pivotal concern with targeting MCL1 has been potential cardiac toxicity, given the protein’s role in heart function. Encouragingly, evaluations of cardiac models demonstrated that this AUTAC approach induced minimal toxicity while maintaining potent anti-cancer activity. Moreover, preliminary evidence suggests that this strategy may extend beyond multiple myeloma, effectively degrading MCL1 in non-small cell lung cancer, hinting at broader oncological applications.

The VCU team plans to refine the AUTAC molecule through medicinal chemistry to enhance its potency and selectivity before advancing to further preclinical testing. Their work not only opens new therapeutic possibilities for multiple myeloma but also encourages exploration of autophagy-mediated degradation pathways in other MCL1-dependent malignancies, such as breast cancer and melanoma.

This study exemplifies how clever manipulation of intracellular degradation systems can transform treatment landscapes, turning a cancer cell’s defense mechanism against itself. By integrating autophagy-targeted degradation with established proteasome inhibition, researchers may have unveiled a potent weapon in the fight against resistant cancers.

Subject of Research: Multiple myeloma, targeted protein degradation, autophagy, proteasome inhibition
Article Title: Proteasome inhibition enhances lysosome-mediated targeted protein degradation
News Publication Date: 11-May-2026
Web References: http://dx.doi.org/10.1038/s41419-026-08835-6
Keywords: Multiple myeloma, proteasome inhibitors, autophagy, targeted protein degradation, MCL1, cancer therapy, lysosome-mediated degradation

The investigation pooled data from three major randomized controlled clinical trials—MAIA, POLLUX, and CASTOR—encompassing a diverse cohort of 1,804 participants with a median age of 66. Approximately half received daratumumab-inclusive regimens, whereas the remainder were treated with therapies devoid of the monoclonal antibody. Prior to treatment initiation, all patients completed a standardized questionnaire designed to evaluate their physical functionality—essentially measuring their ability to perform everyday activities such as walking, dressing, and basic self-care.

Analyses revealed striking associations between baseline patient-reported physical function and clinical outcomes following daratumumab therapy. Remarkably, those reporting lower physical function before treatment initiation derived the most substantial survival benefit. This subgroup experienced a 47% reduction in all-cause mortality risk and a 66% lower risk of disease progression compared to similar patients who did not receive daratumumab. These hazard ratios—0.53 for death and 0.34 for progression—highlight the profound impact that daratumumab confers on patients facing pronounced physical challenges.

In contrast, patients with higher self-reported physical function exhibited a considerably attenuated benefit. For this physically robust group, daratumumab reduced the risk of death by only 14%, a difference that lacked statistical significance, though it did confer a moderate 47% reduction in cancer progression risk. This dichotomy suggests that patient-reported physical function not only forecasts survival outcomes but also predicts differential treatment efficacy, underscoring the need for nuanced therapeutic decision-making.

Interestingly, conventional clinical metrics such as the Eastern Cooperative Oncology Group Performance Status (ECOG-PS)—a physician-assessed scale ranging from fully active to deceased—did not reliably identify which patients would benefit most from daratumumab. Despite ECOG’s widespread use, the study’s lead author Dr. Ahmad Abuhelwa emphasized its limitations: “Patients deemed ‘fully active’ by ECOG often disclosed substantial physical impairments in their self-assessments.” This discrepancy highlights a critical blind spot in clinician-centered evaluation paradigms.

The researchers argue that integrating patient-reported outcomes (PROs) like physical function into routine clinical workflows substantially enhances predictive accuracy for survival and treatment response. Such integration offers a low-cost, pragmatic strategy that is particularly valuable in assessing older or frail multiple myeloma patients, who face elevated risks of therapy-related toxicity and disease progression. Importantly, daratumumab was not associated with increased serious adverse events even in those with diminished physical performance, alleviating concerns about treatment tolerability in vulnerable populations.

This pivotal study thereby champions a paradigm shift towards truly patient-centered oncology care, where subjective experiences and self-reported functional statuses inform and guide therapeutic choices. Embracing this approach not only fosters precision medicine but also aligns treatment plans with individual patients’ lived realities and capabilities, potentially enhancing adherence, outcomes, and overall well-being.

The global burden of multiple myeloma continues to escalate, with projections indicating a staggering 71% increase in incidence and 79% rise in mortality by 2045. In the United States alone, the anticipated numbers for 2025 include over 36,000 new cases and more than 12,000 deaths. Against this backdrop, optimizing the use of life-extending treatments like daratumumab becomes paramount. This study’s demonstration that patient-reported physical function can stratify patients for maximal benefit holds immense promise to improve survival trajectories on a broad scale.

Collaboration between research institutions in the United States, Australia, and the United Arab Emirates underscores the international relevance and robustness of these findings. By pooling expertise from entities such as the H. Lee Moffitt Cancer Center, Flinders University, the University of North Carolina, and Burjeel Cancer Institute, the study harnessed a global perspective, enriching both its methodology and applicability.

Experts in the oncology community have lauded the investigation’s insights. Co-author Dr. Ashley Hopkins stressed the significance of incorporating patient voices into treatment planning, calling it “a critical reminder to clinicians to listen carefully to their patients’ functional status before starting therapy.” Similarly, co-author Prof. Humaid Al-Shamsi highlighted the move towards more compassionate, individualized cancer care, particularly for older or physically vulnerable populations.

Despite its compelling data, the study authors emphasize the necessity for further prospective research to validate these results and to evaluate whether patient-reported physical function can predict responses to other emerging multiple myeloma therapies. They advocate for widespread adoption of patient-reported outcomes in both clinical trials and standard oncology practice, which may catalyze a more responsive and adaptable treatment landscape.

In sum, this landmark research identifies patient-reported physical function at baseline as a potent biomarker that can refine prognosis and tailor daratumumab therapy for multiple myeloma. It challenges the status quo of physician-only assessments, compelling the oncological community to rethink treatment algorithms. By integrating patient insights, clinicians can better discern who will reap the greatest—or more modest—benefit, ushering in an era of more equitable, effective, and personalized cancer care.

Subject of Research: People

Article Title: Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma

News Publication Date: 14-Mar-2025

Web References:
http://dx.doi.org/10.1111/ejh.14410

Image Credits: European Journal of Haematology (2025)

Keywords: Clinical medicine, Oncology, Multiple Myeloma, Patient-Reported Outcomes, Daratumumab, Prognostic Biomarkers, Personalized Medicine